Peptides DB
Research-centric peptide and protocol reference hub
Study 3 of 9BPC-157 literaturePubMed · Review2023

Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing.

BPC-157 shows potential in musculoskeletal healing based on animal studies, but human data is extremely limited, necessitating caution in its use.

Read at PubMedAdd to compare

Where it sits

this study against the rest of the bpc-157 corpus
3
Preclinical
4
Observational
0
Open-label
0
Randomised
2
Reviews · this one

Summary and findings

This narrative review evaluates the molecular mechanisms, therapeutic potential, and safety concerns of Body Protective Compound-157 (BPC-157) in musculoskeletal healing. It highlights the compound's regenerative properties observed in numerous animal models and notes the limited human data available, with only three pilot studies reported. No adverse effects were documented in these studies, but the authors emphasize the need for rigorous clinical trials.

How much of this paper we could read: partial text (0.60). We had some abstract detail. Check the source for anything decisive. What this means →
Not reported in abstract.2023

Abstract

The authors’ words, as PubMed supplied them

PURPOSE OF REVIEW: This scoping review aims to evaluate the molecular mechanisms, therapeutic potential, and safety concerns of Body Protective Compound-157 (BPC-157) in the context of musculoskeletal healing. Given the compound’s increasing availability, popularity, and its regulatory controversies, we sought to assess the breadth and quality of preclinical and clinical data supporting its use in musculoskeletal medicine. RECENT FINDINGS: BPC-157 is a synthetic pentadecapeptide originally isolated from gastric juice and has demonstrated regenerative properties across numerous animal models. It activates several overlapping pathways, notably VEGFR2 and nitric oxide synthesis via the Akt-eNOS axis, promoting angiogenesis, fibroblast activity, and neuromuscular stabilization. It also engages ERK1/2 signaling, facilitates endothelial and muscle repair, and exerts anti-inflammatory effects. These effects promote angiogenesis, fibroblast activity, and neuromuscular stabilization, particularly in poorly vascularized tissues such as tendons and myotendinous junctions. Despite broad preclinical support, human data are extremely limited. Only three pilot studies have examined BPC-157 in humans, including its use for intraarticular knee pain, interstitial cystitis, and intravenous safety/pharmacokinetics. No adverse effects were reported, but rigorous, large-scale trials are lacking. BPC-157 demonstrates robust regenerative and cytoprotective effects in preclinical studies, positioning it as a potentially valuable tool in musculoskeletal medicine. Despite its growing popularity among athletes and its wide availability through non-regulated sources, there is minimal human data available. Until well-designed clinical trials are conducted, BPC-157 should be considered investigational, and its use approached with caution. This review highlights that given the robust preclinical evidence and high public interest, there is a critical need for well-designed human trials to assess the safety, efficacy, and clinical utility of BPC-157 in musculoskeletal medicine.

Background

The paper addresses the role of BPC-157 in musculoskeletal healing, an area of interest due to the peptide's proposed regenerative properties. Prior studies have suggested potential benefits of BPC-157 in tissue repair, but comprehensive reviews are limited. This study is significant as it aims to consolidate existing knowledge and evaluate the implications for clinical use.

Methods

This is a narrative review, and thus does not involve a specific study design or population. The review synthesizes findings from various studies related to BPC-157 and its effects on musculoskeletal healing. No specific n, dose, or duration is reported.

Results

Not reported in abstract.

Interpretation

The review summarizes existing literature on BPC-157 but does not provide new data or insights. Without quantitative findings, it is challenging to determine the clinical relevance of BPC-157 based on this review alone. The lack of robust evidence and potential confounding factors in the studies reviewed may limit the conclusions drawn about its efficacy.

Key findings

  • Not reported in abstract.

Limitations

  • Not a primary research study, but a narrative review.
  • No quantitative results or specific findings reported.
  • Lacks clarity on study design and methodologies of referenced studies.
  • Potential bias due to the nature of narrative reviews.

Elsewhere in the BPC-157 corpus

CProtective effects of BPC 157 in rats with experimentally induced lower extremity ischemia-reperfusion injury.Scientific reports · 2026 · n=30 · Not reported in abstract.AnimalCBPC-157 and Its Novel Hybrid Analogs as Inhibitors of Acetylcholinesterase.PubMed · 2026 · IC50 value of CIARA-1 = 2.52 mM.In vitroDEvaluation of Research Grade Peptides Marketed Directly to Consumers Reveals Extensive Variability in Purity and Measured Abundancebiorxiv-preprint · 2020 · n=50 · 41.6% to 71.1% of samples failed to meet basic quality criteria.CBPC-157 and Its Novel Hybrid Analogs as Inhibitors of Acetylcholinesterase.europepmc · 2023 · IC50 for CIARA-1 = 2.52 mMIn vitroBEndothelium-Dependent Nitric Oxide-Mediated Vasorelaxant Effects of BPC 157 in Human Internal Mammary Artery.PubMed · 2026 · Not reported in abstract.HumanDSemantic Scholar search for BPC-157SemanticScholar · 2010